AI is a game of kings, and OpenAI knows it
Director Melinda Brown of Precision BioSciences Inc (NASDAQ:DTIL) acquired 1,400 shares of common stock on September 22, 2025, at a price of $4.89, in one transaction. The total value of the purchase was $6846. The purchase comes as the stock shows strong momentum, gaining nearly 8% in the past week. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 5.18. Following the transaction, Brown directly owns 21,965 shares of Precision BioSciences Inc . The micro-cap company, valued at $57.52M, holds more cash than debt on its balance sheet. InvestingPro analysis reveals 10+ additional insights about DTIL’s financial health and market position.
In other recent news, Precision BioSciences has reported promising early results from its Phase 1 ELIMINATE-B trial of the PBGENE-HBV gene editing therapy for chronic hepatitis B. The therapy showed substantial viral reductions in patients, with no serious adverse events reported, indicating a favorable safety profile. Additionally, the company has secured a U.S. patent for its PBGENE-HBV therapy, extending protection until March 2042, which follows similar patents granted earlier this year in Europe and Hong Kong.
In another development, Precision BioSciences announced updated employment agreements for its key executives, reflecting current salaries and revised severance terms. Furthermore, the U.S. Food and Drug Administration granted Orphan Drug Designation to Precision BioSciences for its PBGENE-DMD treatment for Duchenne muscular dystrophy, a rare genetic disorder. These developments highlight the company’s ongoing efforts in advancing its gene editing programs and securing intellectual property protection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.